William Y. Go, Ph.D.
Affiliations: | 2004 | University of California, San Diego, La Jolla, CA |
Area:
Immunology, Animal Physiology Biology, Molecular BiologyGoogle:
"William Go"Parents
Sign in to add mentor| Steffan N. Ho | grad student | 2004 | UCSD | |
| (The role of the mammalian osmotic stress response in adaptive immunity: New insights from studies of the NFAT5/TonEBP transcription factor.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Kamb A, Go WY. (2020) Cancer T-cell therapy: building the foundation for a cure. F1000research. 9: 1295 |
| Locke FL, Rossi JM, Neelapu SS, et al. (2020) Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Advances. 4: 4898-4911 |
| Chen PH, Lipschitz M, Weirather JL, et al. (2020) Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T-cell therapy. Jci Insight |
| Locke FL, Go WY, Neelapu SS. (2019) Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma: A Review. Jama Oncology. 1-10 |
| Rossi JM, Galon J, Chang E, et al. (2019) Abstract CT153: Pretreatment immunoscore and an inflamed tumor microenvironment (TME) are associated with efficacy in patients (Pts) with refractory large B cell lymphoma treated with axicabtagene ciloleucel (Axi-Cel) in ZUMA-1 Clinical Trials. 79 |
| Neelapu SS, Ghobadi A, Jacobson CA, et al. (2019) 2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma Biology of Blood and Marrow Transplantation. 25: S65 |
| Lee DW, Santomasso BD, Locke FL, et al. (2018) ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation |
| Locke FL, Ghobadi A, Jacobson CA, et al. (2018) Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. The Lancet. Oncology |
| Locke FL, Ghobadi A, Lekakis LJ, et al. (2018) Outcomes by prior lines of therapy (LoT) in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B cell lymphoma. Journal of Clinical Oncology. 36: 3039-3039 |
| Locke FL, Ghobadi A, Jacobson CA, et al. (2018) Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma. Journal of Clinical Oncology. 36: 3003-3003 |